Next Article in Journal
Knowledge and Perceptions of Adverse Events Following Immunization among Healthcare Professionals in Africa: A Case Study from Ghana
Previous Article in Journal
Simultaneous Administration of Recombinant Measles Viruses Expressing Respiratory Syncytial Virus Fusion (F) and Nucleo (N) Proteins Induced Humoral and Cellular Immune Responses in Cotton Rats
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Vaccines 2019, 7(1), 29; https://doi.org/10.3390/vaccines7010029

Plasmid DNA-Based Alphavirus Vaccines

PanTherapeutics, 1095 Lutry, Switzerland
Received: 14 February 2019 / Revised: 1 March 2019 / Accepted: 4 March 2019 / Published: 8 March 2019
(This article belongs to the Special Issue Advances in DNA Vaccines)
Full-Text   |   PDF [248 KB, uploaded 14 March 2019]   |   Review Reports

Abstract

Alphaviruses have been engineered as vectors for high-level transgene expression. Originally, alphavirus-based vectors were applied as recombinant replication-deficient particles, subjected to expression studies in mammalian and non-mammalian cell lines, primary cell cultures, and in vivo. However, vector engineering has expanded the application range to plasmid DNA-based delivery and expression. Immunization studies with DNA-based alphavirus vectors have demonstrated tumor regression and protection against challenges with infectious agents and tumor cells in animal tumor models. The presence of the RNA replicon genes responsible for extensive RNA replication in the RNA/DNA layered alphavirus vectors provides superior transgene expression in comparison to conventional plasmid DNA-based expression. Immunization with alphavirus DNA vectors revealed that 1000-fold less DNA was required to elicit similar immune responses compared to conventional plasmid DNA. In addition to DNA-based delivery, immunization with recombinant alphavirus particles and RNA replicons has demonstrated efficacy in providing protection against lethal challenges by infectious agents and tumor cells. View Full-Text
Keywords: alphaviruses; layered RNA/DNA vectors; DNA vaccines; RNA replicons; recombinant particles; tumor regression; protection against tumor challenges and infectious agents alphaviruses; layered RNA/DNA vectors; DNA vaccines; RNA replicons; recombinant particles; tumor regression; protection against tumor challenges and infectious agents
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lundstrom, K. Plasmid DNA-Based Alphavirus Vaccines. Vaccines 2019, 7, 29.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top